- Home
- ORMP vs PRQR Comparison
ORMP vs PRQR Comparison
Compare ORMP & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | PRQR |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 167.5M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ORMP | PRQR |
|---|---|---|
| Price | $3.45 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.80 |
| AVG Volume (30 Days) | 98.3K | ★ 406.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.27% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.76 |
| P/E Ratio | $2.29 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $1.82 | $1.08 |
| 52 Week High | $3.76 | $3.10 |
Technical Indicators
Market Signals| Indicator | ORMP | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 51.70 |
| Support Level | $3.21 | $1.34 |
| Resistance Level | $3.72 | $2.30 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 51.22 | 61.90 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.